Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition
- PMID: 39301032
- PMCID: PMC11410642
- DOI: 10.3389/fimmu.2024.1441793
Vaccine induced mucosal and systemic memory NK/ILCs elicit decreased risk of SIV/SHIV acquisition
Abstract
SIV and HIV-based envelope V1-deleted (ΔV1) vaccines, delivered systemically by the DNA/ALVAC/gp120 platform, decrease the risk of mucosal SIV or SHIV acquisition more effectively than V1-replete vaccines. Here we investigated the induction of mucosal and systemic memory-like NK cells as well as antigen-reactive ILC response by DNA/ALVAC/gp120-based vaccination and their role against SIV/SHIV infection. ΔV1 HIV vaccination elicited a higher level of mucosal TNF-α+ and CD107+ memory-like NK cells than V1-replete vaccination, suggesting immunogen dependence. Mucosal memory-like NK cells, systemic granzyme B+ memory NK cells, and vaccine-induced mucosal envelope antigen-reactive IL-17+ NKp44+ ILCs, IL-17+ ILC3s, and IL-13+ ILC2 subsets were linked to a lower risk of virus acquisition. Additionally, mucosal memory-like NK cells and mucosal env-reactive IFN-γ+ ILC1s and env- reactive IL-13+ ILC2 subsets correlated with viral load control. We further observed a positive correlation between post-vaccination systemic and mucosal memory-like NK cells, suggesting vaccination enhances the presence of these cells in both compartments. Mucosal and systemic memory-like NK cells positively correlated with V2-specific ADCC responses, a reproducible correlate of reduced risk of SIV/HIV infection. In contrast, an increased risk was associated with the level of mucosal PMA/Ionomycin-induced IFN-γ+ and CD107+ NKG2A-NKp44- ILCs. Plasma proteomic analyses demonstrated that suppression of mucosal memory-like NK cells was linked to the level of CCL-19, LT-α, TNFSF-12, and IL-15, suppression of systemic env-reactive granzyme B+ memory-like NK cells was associated with the level of OLR1, CCL-3, and OSM, and suppression of IL-17+ ILCs immunity was correlated with the level of IL-6 and CXCL-9. In contrast, FLT3 ligand was associated with promotion of protective mucosal env-reactive IL-17+ responses. These findings emphasize the importance of mucosal memory-like NK cell and envelope- reactive ILC responses for protection against mucosal SIV/SHIV acquisition.
Keywords: SIV/SHIV; V2-specific ADCC; antigen-reactive ILCs; cytokines; innate memory; memory-like NK cells; trained immunity; vaccine (DNA/ALVAC/gp120).
Copyright © 2024 Rahman, Silva de Castro, Schifanella, Bissa and Franchini.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures






Similar articles
-
Loss of HIV candidate vaccine efficacy in male macaques by mucosal nanoparticle immunization rescued by V2-specific response.Nat Commun. 2024 Oct 22;15(1):9102. doi: 10.1038/s41467-024-53359-2. Nat Commun. 2024. PMID: 39438480 Free PMC article.
-
Differential Effect of Mucosal NKp44+ Innate Lymphoid Cells and Δγ Cells on Simian Immunodeficiency Virus Infection Outcome in Rhesus Macaques.J Immunol. 2019 Nov 1;203(9):2459-2471. doi: 10.4049/jimmunol.1900572. Epub 2019 Sep 25. J Immunol. 2019. PMID: 31554692 Free PMC article.
-
Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses.Clin Immunol. 2014 Aug;153(2):308-22. doi: 10.1016/j.clim.2014.05.008. Epub 2014 Jun 4. Clin Immunol. 2014. PMID: 24907411 Free PMC article.
-
Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design.Int Rev Immunol. 2009;28(1):20-48. doi: 10.1080/08830180802684331. Int Rev Immunol. 2009. PMID: 19241252 Free PMC article. Review.
-
Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV.Curr Opin HIV AIDS. 2019 Jul;14(4):309-317. doi: 10.1097/COH.0000000000000551. Curr Opin HIV AIDS. 2019. PMID: 30994501 Free PMC article. Review.
Cited by
-
Loss of HIV candidate vaccine efficacy in male macaques by mucosal nanoparticle immunization rescued by V2-specific response.Nat Commun. 2024 Oct 22;15(1):9102. doi: 10.1038/s41467-024-53359-2. Nat Commun. 2024. PMID: 39438480 Free PMC article.
-
Prospects for therapeutic T-cell vaccine strategies for HIV cure.Curr Opin HIV AIDS. 2025 Sep 1;20(5):463-471. doi: 10.1097/COH.0000000000000965. Epub 2025 Jul 9. Curr Opin HIV AIDS. 2025. PMID: 40638102 Free PMC article. Review.
-
BCG immunization mitigates SARS-CoV-2 replication in macaques via monocyte efferocytosis and neutrophil recruitment in lungs.JCI Insight. 2025 Aug 8;10(15):e194633. doi: 10.1172/jci.insight.194633. eCollection 2025 Aug 8. JCI Insight. 2025. PMID: 40779451 Free PMC article.
References
-
- UNAIDS . World aids day 2023 fact sheet (2023). Available online at: https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_... (Accessed August 2024)
-
- Vaccari M, Fourati S, Gordon SN, Brown DR, Bissa M, Schifanella L, et al. . Hiv vaccine candidate activation of hypoxia and the inflammasome in cd14(+) monocytes is associated with a decreased risk of sivmac251 acquisition. Nat Med. (2018) 24:847–56. doi: 10.1038/s41591-018-0025-7 - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous